NeoPharm Co., Ltd. (092730) Financial Statements

― Followers

NeoPharm Co., Ltd. Financial Overview

NeoPharm Co., Ltd.'s market cap is currently ₩342.54B. The company's EPS TTM is ₩1873.9; its P/E ratio is 6.12; and it has a dividend yield of 5.55%. NeoPharm Co., Ltd. is scheduled to report earnings on August 14, 2026, and the estimated EPS forecast is ₩―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	₩ 132.18B	₩ 119.01B	₩ 97.10B	₩ 85.03B	₩ 87.93B
Gross Profit	₩ 84.71B	₩ 74.03B	₩ 65.39B	₩ 58.38B	₩ 62.39B
Operating Income	₩ 28.77B	₩ 24.65B	₩ 25.31B	₩ 21.44B	₩ 22.43B
EBITDA	₩ 31.88B	₩ 33.35B	₩ 31.01B	₩ 24.95B	₩ 25.37B
Net Income	₩ 27.82B	₩ 23.06B	₩ 23.21B	₩ 17.03B	₩ 17.71B
Balance Sheet
Cash & Short-Term Investments	₩ 141.74B	₩ 126.52B	₩ 111.99B	₩ 113.49B	₩ 105.05B
Total Assets	₩ 220.28B	₩ 192.44B	₩ 177.46B	₩ 155.35B	₩ 143.41B
Total Debt	₩ 1.92B	₩ 629.40M	₩ 1.07B	₩ 412.16M	₩ 558.77M
Net Debt	₩ -24.91B	₩ -17.60B	₩ -10.82B	₩ -10.47B	₩ -6.49B
Total Liabilities	₩ 24.92B	₩ 15.56B	₩ 17.43B	₩ 13.14B	₩ 13.10B
Stockholders' Equity	₩ 195.36B	₩ 176.88B	₩ 160.03B	₩ 142.21B	₩ 130.30B
Cash Flow
Free Cash Flow	₩ 27.23B	₩ 15.55B	₩ 2.43B	₩ 17.35B	₩ 21.20B
Operating Cash Flow	₩ 28.41B	₩ 18.63B	₩ 23.26B	₩ 18.16B	₩ 21.68B
Investing Cash Flow	₩ -9.60B	₩ -6.22B	₩ -16.35B	₩ -8.80B	₩ -16.69B
Financing Cash Flow	₩ -10.18B	₩ -6.50B	₩ -5.92B	₩ -5.75B	₩ -9.52B

Currency in KRW

NeoPharm Co., Ltd. Earnings and Revenue History

Income Statement >

NeoPharm Co., Ltd. Debt to Assets

Balance Sheet >

NeoPharm Co., Ltd. Cash Flow

Cash Flow >

NeoPharm Co., Ltd. Forecast EPS vs Actual EPS

Earnings >